SVF Endurance (Cayman) Ltd 3
3 · Vir Biotechnology, Inc. · Filed Oct 10, 2019
Insider Transaction Report
Form 3
SVF Endurance (Cayman) Ltd
10% Owner
Holdings
- (indirect: See Footnote)
Series A-1 Convertible Preferred Stock
→ Common Stock (15,555,555 underlying) - (indirect: See Footnote)
Series B Convertible Preferred Stock
→ Common Stock (6,111,111 underlying)
Footnotes (2)
- [F1]The Series A-1 Convertible Preferred Stock and the Series B Convertible Preferred Stock are each convertible into Vir Biotechnology, Inc. common stock, have no expiration date and will convert into common stock automatically upon completion of the issuer's initial public offering.
- [F2]SVF Endurance (Cayman) Limited is a wholly-owned subsidiary of SoftBank Vision Fund (AIV M1) L.P. ("SVF"). SB Investment Advisers (UK) Limited ("SBIA UK") has been appointed as alternative investment fund manager ("AIFM") and is exclusively responsible for managing SVF in accordance with the Alternative Investment Fund Managers Directive and is authorized and regulated by the UK Financial Conduct Authority accordingly. As AIFM of SVF, SBIA UK is exclusively responsible for making all decisions related to the acquisition, structuring, financing, voting and disposal of SVF's investments. SBIA UK is wholly owned by SoftBank Group Corp.